65,437 trials
Congenital Bleeding Disorder · Haemophilia A
Primary: The Incidence Rate of FVIII-inhibitors ≥0.6 BU: After Approximately 19 Months — 0.006; 0 Inhibitor rate
Itch
Primary: Absolute NRS Itch Score at Week 16 (End of Treatment) — 7; 7.5 Units on a scale
Pregnant Women
Primary: Success of Anesthesia — 4; 4; 4; 1 Participants
Endometriosis
Primary: Diagnostic Yield — 81; 25 participants
Refractory Multiple Myeloma
Primary: Find Maximum Tolerated Dose (MTD) of Bortezomib in Combination With Pomalidomide and Dexamethasone Out to 2.5 Years, by Count of Patients With Dose Limiting Toxicities…
Metabolism and Nutrition Disorder · Obesity
Primary: Relative Change in Body Weight (%) — -5.99; -8.62; -11.60; -11.17 Percentage (%) of body weight — p==0.0055
Neuromyelitis Optica
Primary: Acceptability as Assessed by the Number of Participants Responding Yes to a Question — 7; 5 Participants
Obstructive Sleep Apnea
Primary: The Apnea Hypopnea Index — 40.5; 46.1 Events per Hour of Sleep
End Stage Liver Disease
Primary: Patient Satisfaction — 45 Participants
Coronary Artery Disease · Aortic Valve Disorder · Heart Failure
Primary: Subject's Percentage of Long Term Safety Performance — 1.5; 2.7; 0.2; 0.4 Percentage of events/late patient years
Large B Cell Lymphoma
Primary: Progression-Free Survival Rate at 2 and 5 Years — 78.9; 75.5; 68.0; 66.0 percentage of participants — p=0.6519
Erythropoietic Protoporphyria · EPP · X-Linked Protoporphyria
Primary: The Hospital Anxiety and Depression Scale (HADS) — 4.6; 1.9 score on a scale
Graft Versus Host Disease
Primary: GVHD-free Survival Rate — 33.3 percentage of patients
Perioperative Chest Pain
Primary: Pain Disability Index Score (PDI) at Six Months Following Surgical Procedure — 26; 30; 12; 13 units on a scale — p=0.28
Ventricular Tachycardia
Primary: Freedom From First Event Requiring ICD Therapy — 62.5; 50; 62.5; 37.5 probability of freedom